Should gastroprotective agents be given with COX-2 inhibitors? A question worthy of scrutiny

Joint Bone Spine

Volumn 71, Issue 6, 2004, Pages 454-456

  Bertin, Philippe ^a  

^a DUPUYTREN UNIVERSITY HOSPITAL   (France)

Author keywords

COX 2 inhibitors; Gastroprotective agents

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; MISOPROSTOL; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PARACETAMOL; PROTON PUMP INHIBITOR; ROFECOXIB;

DIGESTIVE SYSTEM PERFORATION; DIGESTIVE SYSTEM ULCER; DRUG EFFICACY; DRUG SAFETY; EDITORIAL; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL TOXICITY; HUMAN; MUSCULOSKELETAL DISEASE; NONHUMAN; OSTEOARTHRITIS; RHEUMATOID ARTHRITIS; RISK BENEFIT ANALYSIS;

ARTHRITIS; CYCLOOXYGENASE INHIBITORS; DRUG THERAPY, COMBINATION; GASTROINTESTINAL AGENTS; HUMANS; STOMACH DISEASES;

EID: 10344221019     PISSN: 1297319X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jbspin.2004.01.004     Document Type: Editorial

References (17)

1. Faggionato D., Pigeon M., Naudin F., Sermet C., Fagnani F., Le Jeunne P. La diffusion des anti-COX-2 dans la prescription des médecins. Bulletin d'information en économie de la santé 12:2002;1-6
2. Geis G.S., Hubbard R.C., Yu S., Zhao Skokie W. Efficacy and tolerability of celecoxib: a comparison of once daily versus twice daily dosing. Arthritis Rheum. 42:(S):1999;S144
3. Ehrich E.W., Schnitzer T.J., McIiwain H., Levy R., Wolfe F., Weisman M., et al. Effect of specific COX-2 inhibition in osteoarthritis of the knee: a 6 week double blind, placebo controlled pilot study of rofecoxib. J Rheumatol. 26:1999;2438-2447. Rofecoxib Osteoarthritis Pilot Study Group
4. Simon L.S., Lanza F.L., Lipsky P.E., Hubbard R.C., Talwalker S., Schwartz B.D., et al. Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase-2 inhibitor: efficacy and safety in two placebo-controlled trials in osteoarthritis and rheumatoid arthritis, and studies of gastro-intestinal and platelet effect. Arthritis Rheum. 41:1998;1591-1602
5. Schnitzer T.J., Truitt K., Fleischmann R., Dalgin P., Block J., Zeng Q., et al. The safety profile, tolerability, and effective dose range of rofecoxib in the treatment of rheumatoid arthritis. Clin Ther. 21:1999;1688-1702
6. Chan C.C., Boyce S., Brideau C., Ford-Hutchinson A.W., Gordon R., Gu D., et al. Pharmacology of a selective cyclooxygenase-2 inhibitor, L-745, 337: a novel nonsteroidal antiinflammatory agent with an ulcerogenic sparing effect in rat and non human primate stomach. J Pharmacol Exp Ther. 274:1995;1531-1537
7. Futaki N., Yoshikawa K., Hamasaka Y., Arai I., Higuchi S., Iizuka H., et al. NS-398, a novel non-steroid anti-inflammatory drug with potent analgesic and antipyretic effects, which causes minimal stomach lesions. Gen Pharmacol. 24:1993;105-110
8. Lanza F.L., Rack M.F., Simon J., Quan H., Bolognese J.A., Hoover M.E., et al. Specific inhibition of cyclooxygenase-2 with MK-0966 is associated with less gastroduodenal damage than either aspirin or ibuprofen. Aliment Pharmacol Ther. 13:1999;761-767
9. Silverstein F.E., Faich G., Goldstein J.L., Simon L.S., Pincus T., Whelton A., et al. Gastrointestinal toxicity with celecoxib vs. nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib long-term arthritis safety study. J Am Med Assoc. 284:2000;1247-1255
10. Bombardier C., Laine L., Reicin A., Shapiro D., Burgos-Vargas R., Davis B., et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR study group. New Engl J Med. 343:2000;1520-1528
11. Mandani M., Rochon P., Juurlink D., Kopp A., Anderson G., Naglie G., et al. Observational study of upper gastrointestinal haemorrhage in elderly patients given selective cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs. Br Med J. 325:2002;624-627
12. Avouac B., Berenbaum F., Bertin P., Chaussade S., Combe B., Florent C., et al. Une protection digestive doit-elle être associée à la prescription d'un coxib. « les coxibs: les inhibiteurs spécifiques de COX-2 » 2002;75 ed. La Simarre
13. Vidal. 78 édition:2002;Le dictionnaire, 2, rue Béranger 75003, Paris
14. Wolfe F., Anderson J., Burke T., Arguelles L., Pettitt D. Gastroprotective therapy and risk of gastrointestinal ulcers: risk reduction by COX-2 therapy. J Rheumatol. 29:2002;467-473
15. Rhame E., Marentette M., Kong S., Lelorier J. Use of NSAIDs, COX-2 inhibitors, and acetaminophen and associated coprescriptions of gastroprotective agents in an elderly population. Arthritis Rheum. 47:2002;595-602
16. Chan F., Hung L., Bing Y., Suen B., Wu J., Lee C., et al. Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis. New Engl J Med. 347:2002;2104-2110
17. Laine L., Bombardier C., Hawkey C., Davis B., Shapiro D., Brett C., et al. Stratifying the risk of NSAID-related upper gastrointestinal clinical events: results of a double blind outcomes study in patients with rheumatoid arthritis. Gastroenterology. 123:2002;1006-1012